This process induces robust cuproptosis, upregulates PD-L1 expression, and promotes the release of DAMPs, thereby synergizing with anti-PD-L1 immunotherapy to enhance anti-tumor immunity (Table 1) (Li et al., 2023). The gene discussed is CD274; the disease is neoplasm.